Trial Profile

Randomized Phase III Trial of Chemotherapy vs. Pembrolizumab Plus Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 04 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Bendamustine; Brentuximab vedotin; Carboplatin; Doxorubicin; Etoposide; Gemcitabine; Ifosfamide; Vinorelbine
Indications Hodgkin's disease
Focus Diagnostic use; Therapeutic Use

Most Recent Events

30 Aug 2023 Planned initiation date changed from 1 Apr 2023 to 10 Aug 2023.
30 Aug 2023 Status changed from not yet recruiting to withdrawn prior to enrolment (Protocol moved to Withdrawn).
07 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com